Breast Cancer: Targets and Therapy

Breast Cancer: Targets and Therapy is pleased to announce an upcoming Article Collection dedicated to the transformative role of antibody-drug conjugates in the treatment of breast cancer. 

Antibody-drug conjugates (ADCs) consist of monoclonal antibodies linked to cytotoxic drugs, allowing for selective delivery of the therapeutic agent directly to cancer cells and minimizing damage to healthy tissues. Advances in ADC research have led to numerous approvals for clinical use, with significant impact on breast cancer therapy, as ADCs can effectively reduce tumor size and improve progression-free survival. With the ongoing identification of novel targets and indications, ADCs are poised to become a leader in the era of targeted therapies for breast cancer. 

We welcome submissions of original research articles, reviews, and perspectives that contribute to the understanding and advancement of these therapies, including mechanisms of action, clinical efficacy, optimal combinations and ordering, and understanding and overcoming resistance. 

This Article Collection will be included in a wider Game Changer Series focused on breakthrough therapies across medicine. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis and Dove Medical Press, increasing the discoverability and visibility of your research.

The deadline for submissions is 1 June 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, enter the code NRLJP when prompted during submission. 

Please contact Commissioning Editor Cassie Houtz at [email protected] with any questions.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Breast Cancer Biomarkers in Diagnostic and Translational Pathology" in Breast Cancer: Targets and Therapy.

Breast cancer diagnostics has undergone a significant transformation with the expanding integration of immunohistochemistry-based biomarker assessment into routine pathology practice. Beyond traditional morphologic classification, contemporary evaluation increasingly incorporates predictive and prognostic markers. In breast pathology, biomarkers such as hormone receptors and HER2 have long served as foundational tools; however, recent developments have broadened this landscape to include more nuanced categories of expression and emerging targets. This evolving framework reflects a shift toward more refined histopathologic evaluation. As a result, breast cancer pathology now sits at the intersection of diagnostic evaluation and translational science, with biomarker assessment forming a core component of how these tumors are classified and understood.

Breast cancer diagnostics has undergone a significant transformation with the expanding integration of immunohistochemistry-based biomarker assessment into routine pathology practice. Beyond traditional morphologic classification, contemporary evaluation increasingly incorporates predictive and prognostic markers. In breast pathology, biomarkers such as hormone receptors and HER2 have long served as foundational tools; however, recent developments have broadened this landscape to include more nuanced categories of expression and emerging targets. This evolving framework reflects a shift toward more refined histopathologic evaluation. As a result, breast cancer pathology now sits at the intersection of diagnostic evaluation and translational science, with biomarker assessment forming a core component of how these tumors are classified and understood.

This Article Collection will focus on investigating immunohistochemical and molecular biomarker testing in breast cancer, with particular emphasis on optimizing reproducibility and standardization in routine practice.

Topics of interest include (but are not limited to):

• Technical and interpretative challenges that pathologists and oncologists must consider, especially in the assessment of low and ultra-low HER2 expression and their implications for targeted therapies.
• Predictive biomarkers in breast cancer immunotherapy, as well as emerging markers that inform treatment selection and response.
• Integration of digital pathology approaches and translational surgical pathology studies.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

The deadline for submissions is 31 January 2027. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code C2928 to indicate that your submission is for consideration in this Article Collection.

Please contact Rebecca Turner at [email protected] with any questions or requests for discount codes relating to this Article Collection.

Guest Advisors

Dr. Eyas Alzayadneh is a surgical pathologist with training in gynecologic and breast pathology. His work focuses on the integration of histopathologic, immunohistochemical, and molecular features in tumor evaluation and clinical practice. He has contributed to research across multiple areas of cancer pathology, with an interest in biomarker-based diagnostics and their clinical applications.

Dr. Rofieda Radi Abdel Rahman Alwaqfi is an Assistant Professor of Pathology at the Johns Hopkins Hospital.

View all papers in this article collection